Insight Molecular Diagnostics (IMDX) Profit After Tax (2015 - 2026)

Insight Molecular Diagnostics has reported Profit After Tax for 12 years, with the latest figure at -$4.3 million in Q1 2026.

• Quarterly Profit After Tax rose 35.69% year-over-year to -$4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$47.8 million (up 18.18% YoY) and the FY2025 annual result came in at -$50.2 million, up 17.57% from the prior year.
• Profit After Tax advanced to -$4.3 million in Q1 2026 per IMDX's latest filing, from -$23.0 million in the prior quarter.
• Over five years, Profit After Tax peaked at $6.0 million in Q1 2023 and troughed at -$44.7 million in Q4 2022.
• A 5-year average of -$12.5 million and a median of -$9.6 million in 2022 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax surged 157.9% in 2023, then slumped 253.2% in 2024.
• Over 5 years, Profit After Tax stood at -$44.7 million in 2022, then jumped by 64.21% to -$16.0 million in 2023, then slumped by 111.19% to -$33.8 million in 2024, then soared by 32.03% to -$23.0 million in 2025, then jumped by 81.31% to -$4.3 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$4.3 million, -$23.0 million, and -$10.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.